The FDA has distinguished between mass-marketed compounded products and patient-specific compounding performed under Section 503A of the FD&C Act, which may remain permissible in narrow circumstances where a patient's medical needs cannot be met by an FDA-approved drug
Urticaria, pruritus without rash, and angioedema have been reported in less than one percent of patients
Write the reconstitution date on the vial using a permanent marker
If you are experiencing significant gastrointestinal side effects, adjusting your diet and increasing fluid intake are the first steps
A patient in a medically supervised program can receive guidance on protein targets, exercise strategy, dose tolerance, hydration, digestion, lab markers, and adjunctive therapies when appropriate
However, some clinicians may prescribe a biweekly dosing schedule off-label as a maintenance strategy once their patients have achieved their weight loss goals